



Short-term Antihyperglycemic and Weight Modulation Effects of *Leuenbergeria bleo* (Kunth) Lodé: Phytochemical Screening and in vivo Assessment in an Alloxan-Induced Diabetic Rat Model

Sheryar Afzal  ^{1,*}, Velaga Venkata Sathya Sai Appalaraju  ², Ali Attiq  ³, Iram Malik  ⁴, Ibrahim Albokhadaim  ¹, Sameer M Alhojaily  ¹, Yuan Seng Wu  ⁵, Yasir A Almofty  ¹, Ahmed Omer Alameen  ¹, Ghazi Aljabl  ²

¹Department of Biosciences, College of Veterinary Medicine, King Faisal University, Hofuf, Saudi Arabia

²Department of Medicinal Chemistry, Faculty of Pharmacy and Biomedical Sciences, MAHSA University, Petaling Jaya, Malaysia

³School of Pharmaceutical Sciences, Universiti Sains Malaysia, George Town, Malaysia

⁴Department of Chemistry, Govt. Graduate College for Women, University of Sargodha, Sargodha, Pakistan

⁵Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Petaling Jaya, Malaysia

*Corresponding Author: Department of Biosciences, College of Veterinary Medicine, King Faisal University, Hofuf, Saudi Arabia. Email: safzal@kfu.edu.sa

Received: 5 August, 2025; Revised: 15 October, 2025; Accepted: 1 November, 2025

Abstract

Background: *Leuenbergeria bleo*, a medicinal plant with traditional therapeutic uses, has attracted interest for its antidiabetic potential.

Objectives: This study evaluated the antihyperglycemic effects of its leaf extracts in an alloxan-induced diabetic rat model.

Methods: The leaves of *L. bleo* were sequentially extracted using petroleum ether, chloroform, and methanol. Phytochemical screening was conducted to identify bioactive compounds such as phytosterols, alkaloids, tannins, and flavonoids. Thirty healthy Albino Wistar rats were divided into five groups. Diabetes was induced in four groups via intraperitoneal injection of alloxan monohydrate (140 mg/kg). The diabetic rats were treated with either chloroform or methanol extracts of *L. bleo* (500 mg/kg/day) for five days, with metformin (100 mg/kg/day) serving as the standard reference treatment. Blood glucose levels were monitored daily, and body weight was recorded on days 1, 3, and 5.

Results: Methanol extract significantly reduced blood glucose levels by 12.23% by day 5, compared to a 6.35% reduction with chloroform extract. Additionally, the methanol extracts mitigated weight loss, resulting in an 8.07% increase in body weight, while the diabetic control group experienced a 26.72% decrease. The effects of the methanol extract were comparable to metformin, though slightly less potent. *Leuenbergeria bleo* exhibits modest antihyperglycemic potential, particularly in its methanol extract, which also stabilizes body weight in diabetic rats.

Conclusions: The presence of flavonoids and alkaloids likely contributes to these effects. Further research is warranted to elucidate the exact mechanisms and explore *L. bleo*'s potential as a natural alternative therapy for diabetes management.

Keywords: *Leuenbergeria bleo*, Diabetes Mellitus, Phytochemicals, Alloxan, Antihyperglycemic Activity

1. Background

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insufficient insulin production or impaired cellular response (1, 2). It is classified into type I, type II, and gestational diabetes, with type II accounting for 90 - 95%

of cases worldwide (3, 4). Lifestyle factors such as obesity and inactivity contribute significantly. In 2021, 537 million adults had diabetes globally, projected to reach 783 million by 2045 (5, 6). Although various antidiabetic drugs exist, many have limitations in long-term efficacy and cause adverse effects, fueling interest in safer, plant-based alternatives.

Copyright © 2025, Afzal et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Afzal S, Venkata Sathya Sai Appalaraju V, Attiq A, Malik I, Albokhadaim I, et al. Short-term Antihyperglycemic and Weight Modulation Effects of *Leuenbergeria bleo* (Kunth) Lodé: Phytochemical Screening and in vivo Assessment in an Alloxan-Induced Diabetic Rat Model. Iran J Pharm Res. 2025; 24 (1): e164873. <https://doi.org/10.5812/ijpr-164873>.

Leuenbergeria bleo (Kunth) Lode, known locally as "Jarum Tujuh Bilah" and "Cak Sing Cam", is a medicinal plant from the Cactaceae family, with approximately 8 accepted species and multiple synonyms (7-9). The species *L. bleo* (Kunth) Lode, formerly recognized as *Pereskia bleo* (Kunth) DC., has undergone taxonomic revision based on molecular phylogenetic evidence. Studies by Butterworth and Wallace and Nyffeler and Eggli revealed that the genus *Pereskia*, as traditionally defined, was paraphyletic, comprising distinct northern and southern evolutionary lineages. In response to these findings, Lode proposed the establishment of the genus *Leuenbergeria*, reclassifying *P. bleo* into this group, which is distinguished by its persistent foliage and woody shrub or tree morphology at the base of the Cactaceae family. Leading botanical databases such as Plants of the World Online (POWO 2024) and World Flora Online now recognize *L. bleo* as the valid name, with *P. bleo* listed as a synonym. This updated nomenclature reflects the current understanding of evolutionary relationships within the cactus family and is recommended for use in contemporary scientific literature (10-14). Native to regions from Brazil to Mexico, it is widely cultivated for its medicinal properties (9). Traditionally, *L. bleo* is used for detoxification, cancer, hypertension, diabetes, gastrointestinal disorders, pain, and inflammatory diseases (9, 15). Scientific studies have examined its anticancer, antihypertensive, antimicrobial, antidiabetic, and analgesic effects (16-20), but conclusive evidence is lacking, especially regarding its antidiabetic activity.

2. Objectives

This study aims to address this gap by evaluating the antihyperglycemic effects of *L. bleo* extracts in an alloxan-induced diabetic rat model. It is hypothesized that antioxidant properties of the extracts protect pancreatic β -cells from oxidative stress. The research also includes screening for active constituents using chromatographic and spectroscopic techniques. The findings could support the development of novel, cost-effective, and safer herbal formulations for diabetes management, providing scientific validation for traditional uses and informing new natural therapeutic approaches amid the global diabetes rise.

3. Methods

3.1. Plant Material Collection

Leuenbergeria bleo leaves were collected in July 2019 from Bukit Mertajam, Penang, and authenticated by Mr. Kamarudin Saleh, botanist at Forest Research Institute Malaysia (FRIM). A voucher specimen (PID 220914-17) was deposited at the FRIM herbarium. Leaves were cleaned, shade-dried, ground to powder, and stored for extraction.

3.2. Preparation of Plant Extracts

Approximately 300 g of powdered leaves were sequentially extracted using petroleum ether, chloroform, and methanol via Soxhlet apparatus. Residual plant material was dried for 48 hours before the next solvent extraction. Extracts were dried with a rotary evaporator at 40°C, yielding petroleum ether (16.79 g), chloroform (15.67 g), and methanol (17.81 g) extracts, which were stored at 4°C until analysis.

3.3. Preliminary Phytochemical Analysis

Qualitative screening for alkaloids, flavonoids, glycosides, tannins, phenolics, and phytosterols was performed using previously reported methods with slight modifications (Table 1) (17).

3.4. Experimental Animals

Thirty healthy Albino Wistar rats (8 - 10 weeks, 180 - 200 g) of either sex were acclimatized for one week under standard conditions (22 ± 2°C, 55 ± 5% humidity, 12 h light/dark cycle) with free access to food and water. Ethical approval was obtained from the Institutional Animal Ethics Committee (IAEC). All procedures involving animals were conducted in accordance with the ARRIVE guidelines and institutional animal welfare protocols. Efforts were made to minimize animal suffering, and the number of animals used was kept to the minimum required to achieve statistical validity.

3.5. Induction of Diabetes

Diabetes was induced via a single intraperitoneal injection of alloxan monohydrate (140 mg/kg) dissolved in saline after 18 h fasting. To prevent fatal hypoglycemia, 5% glucose solution was given for 24 h post-injection. Blood glucose was measured from the

Table 1. Qualitative Phytochemical Tests Used for the Screening of *Leuenbergeria bleo* Extracts

Phytochemical Class Test	Procedure	Positive Result
Carbohydrates and glycosides		
Molisch's test	A small quantity of the extract was dissolved in 4 mL of distilled water, followed by filtration. The filtrate was treated with 2 - 3 drops of 1% alcoholic α -naphthol and 2 mL of concentrated sulfuric acid.	The formation of a brown ring at the junction of the two liquids
Proteins and free amino acids		
Million's test	The extract was dissolved in water, followed by the addition of Million's reagent.	The appearance of a red color
Tannins and phenolic compounds		
Ferric chloride test	2 mL of the extract was treated with 1 mL of 5% ferric chloride solution.	A blue or green coloration
Phytosterols		
Salkowski's test	5 mL of chloroform was added to the extract, followed by a few drops of concentrated sulfuric acid.	The appearance of a brown color
Liebermann-Burchard's test	The extract was dissolved in chloroform, treated with concentrated sulfuric acid and acetic anhydride.	The appearance of a bluish-green color
Alkaloids		
Wagner's	The extract was treated with dilute hydrochloric acid and Wagner's reagent.	The formation of a reddish-brown precipitate
Hager's reagents	The extract was treated with dilute hydrochloric acid and Hager's reagent.	Yellow precipitate
Flavonoids		
Shinoda's test	The extract was dissolved in alcohol, and a small amount of magnesium and concentrated hydrochloric acid was added.	Magenta color

tail vein at 1, 12, 24, and 48 h. Rats with fasting glucose > 200 mg/dL at 48 h were considered diabetic. Six healthy rats served as nondiabetic controls.

3.6. Experimental Design

Diabetic rats were divided into five groups (n = 6 each): Animals were randomly assigned to treatment groups using a computer-generated randomization sequence. Blinding was implemented during outcome assessment, with investigators unaware of group allocation while recording blood glucose and body weight data. These procedures were followed to minimize bias and enhance reproducibility.

Group A (normal control, distilled water orally), group B (diabetic control, distilled water orally), group C (metformin 100 mg/kg/day intraperitoneally), group D (chloroform extract 500 mg/kg/day orally), group E (methanol extract 500 mg/kg/day orally). Treatments lasted 5 days with doses adjusted by body weight.

3.7. Blood Glucose Measurement

Blood glucose was measured daily from days 1 to 5 under fasting conditions via glucometer (Accu-Check Active, Roche Diagnostics, Germany) using tail vein samples at consistent times.

3.8. Body Weight Monitoring

Body weight was recorded on days 1, 3, and 5 using a digital balance to evaluate treatment effects.

3.9. Statistical Analysis

Data are expressed as mean \pm SEM. Statistical significance was assessed by one-way ANOVA with Tukey's post-hoc test using SPSS v19.0; P < 0.05 was considered significant.

4. Results

4.1. Extraction and Qualitative Phytochemical Analysis of *Leuenbergeria bleo* Leaves

The extraction of *L. bleo* leaves using solvents of increasing polarity – petroleum ether, chloroform, and methanol – yielded varying amounts of extract, indicating differential solubilities of the plant's bioactive compounds. Methanol, the most polar solvent used, produced the highest yield at 5.94%, followed by chloroform at 5.60% and petroleum ether at 5.22%. Phytochemical analysis of the *L. bleo* extracts revealed the presence of several key secondary metabolites, including steroids, alkaloids, tannins, phenolic compounds, and flavonoids. The presence of these

Table 2. Screening of Phytochemical Contents of Three Different Extracts of *Leuenbergeria bleo* Leave

Constituent of Detection and Type of Tests	Results ^a		
	Petroleum Ether	Chloroform	Methanol
Carbohydrate			
Molisch test	-	-	-
Proteins and free amino acids			
Millon's test	-	-	-
Steroids and triterpenoids			
Liebermann Burchard test	+	++	+++ ^b
Salkowski test	+	++	+++
Alkaloids			
Wagner's reagent	-	+	++
Hager's reagent	-	+	++
Tannin and Phenolic compound			
5% Ferric Chloride solution test	+	+	++
Flavonoid			
Shinoda test	+	++	+++

^a(+) indicates the presence of secondary metabolites and (-) indicates the absence of secondary metabolites.

^b Stronger positive results.

Table 3. Fasting Blood Glucose Level of Different Groups on Normal Albino Rats (N = 6)^{a,b}

Groups	Blood Glucose Level (mg/dL)
1	105.83 ± 2.69
2	105.17 ± 2.44
3	105.00 ± 1.86
4	103.67 ± 1.65
5	102.17 ± 0.95

^a Values are expressed as mean ± SD.

^b Mean values were not significantly different; P > 0.05.

Table 4. Fasting Blood Glucose Levels in Alloxan Monohydrate Induced Diabetic Rats^a

Experimental Groups	Blood Glucose Level (mg/dL, h) ^b			
	1	12	24	48
Normal control (n = 6) ^c	109.67 ± 3.21	108.33 ± 3.11	107.67 ± 2.43	112.00 ± 2.67
Diabetic induced group (n = 24) ^d	251.17 ± 7.42	278.00 ± 4.20	316.67 ± 4.21	383.33 ± 5.27

^a Values are expressed as mean ± SD.

^b N = 6 for control group and 24 for diabetic group.

^c Not significantly different (P > 0.5) compared with normal group before Alloxan monohydrate.

^d Significantly different (P < 0.5) compared with normal control group before Alloxan monohydrate.

bioactive compounds, particularly in the chloroform and methanol extracts, suggests that these solvents are more effective at isolating compounds with potential pharmacological activities (Table 2).

4.2. Baseline Blood Glucose Levels in Normal Albino Rats

The baseline fasting blood glucose levels were measured in all experimental groups prior to any

Table 5. Effect of Extracts of *Leuenbergeria bleo* on Body Weight in Alloxan Monohydrate Induced Diabetic Rats Over a Five-day-Treatment Period (N = 6)^a

Experimental Groups	Body Weight		
	Day 1	Day 3	Day 5
Normal control	194.50 ± 4.77	193.50 ± 5.21	193.50 ± 4.94
Diabetic control	205.83 ± 4.05 ^{b,c}	155.67 ± 1.84 ^{d,e}	150.83 ± 1.60 ^{d,e}
Standard reference (100 mg/kg/d)	202.67 ± 3.34 ^{b,f}	188.33 ± 3.69 ^{b,g}	190.17 ± 3.65 ^{b,g}
Chloroform extract (500 mg/kg/d)	200.33 ± 4.08 ^{b,f,c}	182.00 ± 6.18 ^{b,g,c}	184.17 ± 6.31 ^{b,g,c}
Methanol extract (500 mg/kg/d)	204.83 ± 4.87 ^{b,f,c}	185.50 ± 4.40 ^{b,g,c}	190.83 ± 5.13 ^{b,g,c}

^aValues are expressed as mean ± SD.

^bNot significantly different compared to the normal group (P > 0.05).

^cNot significantly different compared to the standard group (P > 0.05).

^dSignificantly different compared to the normal group (P < 0.05).

^eSignificantly different compared to the standard group (P < 0.05).

^fNot significantly different compared to the diabetic group (P > 0.05).

^gSignificantly different compared to the diabetic group (P < 0.05).

treatment. The results, as shown in **Table 3**, indicated that the glucose levels were consistent across all groups, with no significant differences observed (P > 0.05). The mean glucose levels ranged from 102 - 106 mg/dL, confirming the homogeneity of the animal model at the beginning of the study. These baseline values provided a reliable reference point for subsequent comparisons following the induction of diabetes and treatment with the plant extracts.

4.3. Blood Glucose Levels Following Alloxan-Induced Diabetes

Following the administration of alloxan monohydrate at a dose of 140 mg/kg (30), a significant increase in blood glucose levels was observed in the diabetic-induced group compared with the normal control group (**Table 4**). The blood glucose levels in the diabetic rats rose sharply within the first 48 hours, increasing by approximately 34% from the initial measurement. This marked elevation in glucose levels confirmed the successful induction of diabetes in the experimental animals.

4.4. Effects of *Leuenbergeria bleo* Extracts on Body Weight in Diabetic Rats

The body weights of the rats were monitored throughout the treatment period to assess the effects of diabetes and the therapeutic potential of the *L. bleo* extracts. As shown in **Table 5**, the diabetic control group presented a significant reduction in body weight over

the 5-day study period, with approximately 26.72% of their initial body weight being lost. In contrast, the groups treated with the chloroform and methanol extracts, as well as the standard metformin group, presented relative stabilization or a slight increase in body weight. The methanol extract group presented a 6.83% increase in body weight, whereas the chloroform extract group presented an 8.07% increase.

4.5. Antihyperglycemic Effects of *Leuenbergeria bleo* Extracts in Diabetic Rats

The antihyperglycemic effects of the *L. bleo* extracts were evaluated by measuring blood glucose levels at days 1, 3, and 5 of treatment. The results indicate that both the chloroform and methanol extracts significantly reduced blood glucose levels in diabetic rats compared with those in the untreated diabetic control group (**Figure 1**). The methanol extract, in particular, had a stronger glucose-lowering effect, reducing blood glucose levels by 12.24% by day 5, whereas a 6.36% reduction was observed with the chloroform extract. The standard reference group treated with metformin presented the most pronounced reduction in glucose levels, with a 25.88% decrease by day 5. The methanol extracts reduced glucose levels by 12.24% (Cohen's *d* = 2.96, 95% CI: 1.72 - 4.20), while the chloroform extract showed a 6.36% reduction (Cohen's *d* = 1.89, 95% CI: 0.91 - 2.87), indicating large to very large effect sizes despite the small sample size.




Figure 1. Antihyperglycemic effect of different extracts of *Leuenbergeria bleo* leaves on alloxan monohydrate-induced diabetic rats

5. Discussion

Diabetes-induced weight loss is primarily due to the catabolic effects of insulin deficiency, leading to muscle wasting and fat breakdown (21, 22). The major finding of this study is that *L. bleo* leaf extracts, particularly the methanol extract, exhibited significant antihyperglycemic effects in alloxan-induced diabetic rats, consistent with their phytochemical profiles. In this study, it was demonstrated that methanol, the most polar solvent, yielded the highest extract amount (5.94%), followed by chloroform (5.60%), which aligns with the presence of bioactive compounds such as flavonoids, alkaloids, tannins, phenolics, and steroids detected in these extracts (Table 2). The presence of flavonoids like quercetin and rutin, known to inhibit carbohydrate-metabolizing enzymes including α -glucosidase, contributes to reducing postprandial glucose levels (23). Alkaloids may further activate the AMPK pathway, enhancing glucose and lipid metabolism (24). Additionally, phenolic acids provide antioxidant properties that help mitigate oxidative

stress, a major factor in pancreatic β -cell dysfunction in diabetes (25). These compounds may act synergistically, amplifying the antihyperglycemic effect of *L. bleo* extracts.

The methanol extract demonstrated the most potent glucose-lowering activity, reducing blood glucose by 12.24% by day 5, followed by the chloroform extract with a 6.36% reduction. Both extracts also contributed to stabilizing body weight, counteracting the 26.72% weight loss observed in untreated diabetic controls. Methanol and chloroform extracts produced weight increases of 6.83% and 8.07%, respectively, comparable to the effects seen with metformin treatment (Table 5). These findings suggest that *L. bleo* extracts alleviate diabetic symptoms, likely through improved glycemic control and attenuation of diabetes-associated catabolism.

Acute oral toxicity studies have confirmed the safety of *L. bleo* extracts up to 2500 mg/kg with no adverse effects reported (26). The phytochemical constituents identified, including phytosterols, alkaloids, tannins, phenolics, and flavonoids, have well-documented

antidiabetic activities in other plants, supporting their contribution to the observed effects in this study.

Overall, *L. bleo* shows promise as a natural antidiabetic agent that may provide a safer, more cost-effective alternative to synthetic drugs. Future research should focus on elucidating the molecular mechanisms underlying its effects, particularly insulin signaling, glucose metabolism, and oxidative stress pathways. Isolation and characterization of the active compounds are essential to facilitate the development of targeted therapies. Furthermore, long-term studies assessing chronic efficacy, safety, dose-response relationships, and effects on lipid metabolism and insulin sensitivity will provide comprehensive insight into the therapeutic potential of *L. bleo*.

5.1. Limitations and Future Directions

This study adopted a five-day treatment protocol to evaluate short-term antihyperglycemic effects. Similar durations have been validated in published models, including Nkono et al. and Omabe et al., which demonstrated significant glucose reductions within this window (27, 28). While suitable for acute-phase assessment, future studies should extend treatment duration to evaluate sustained efficacy and safety. Petroleum ether extract was indeed prepared and subjected to preliminary phytochemical screening. The results indicated minimal presence of bioactive compounds, particularly those relevant to antidiabetic activity. Consequently, it was excluded from in vivo testing to focus on the more pharmacologically promising chloroform and methanol extracts. This rationale has been clarified in the revised methodology section (section 2.2), and the screening results are presented in [Table 2](#). Only a single dose (500 mg/kg) was tested in this study, selected based on prior toxicity data indicating safety up to 2500 mg/kg (26), which aimed to establish preliminary efficacy.

Footnotes

Authors' Contribution: Study concept and design: S. A., A. A., and V. A.; Analysis and interpretation of data: G. A., I. A., S. A., and Y. S. W.; Drafting of the manuscript: S. A. and I. M.; Critical revision of the manuscript for important intellectual content: Y. A., A. O., and Y. S. W.; Statistical analysis: G. A. and V. A.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: This study was conducted in accordance with animal ethics approval granted by the Pharmacy Research Ethics Committee of MAHSA University (PREC/MU/0214). All efforts were made to minimize pain and stress. Animals were monitored daily and handled carefully for invasive procedures.

Funding/Support: This work was supported by the Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia (Grant No. KFU254618.)

References

1. Mukhtar Y, Galalain A, Yunusa U. A Modern Overview on Diabetes Mellitus: A Chronic Endocrine Disorder. *Eur J Biol*. 2020;5(2):1-14. <https://doi.org/10.47672/ejb.409>.
2. Kartika R, Wibowo H. Impaired Function of Regulatory T Cells in Type 2 Diabetes Mellitus. *Mol Cell Biomed Sci*. 2020;4(1). <https://doi.org/10.21705/mcbs.v4i1.64>.
3. Kumar R, Saha P, Kumar Y, Sahana S, Dubey A, Prakash O. A review on diabetes mellitus: type1 & Type2. *World J Pharm Pharm Sci*. 2020;9(10):838-50.
4. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. *Lancet*. 2022;400(10365):1803-20. [PubMed ID: 36332637]. [https://doi.org/10.1016/S0140-6736\(22\)01655-5](https://doi.org/10.1016/S0140-6736(22)01655-5).
5. Soomro MH, Jabbar A. Diabetes etiopathology, classification, diagnosis, and epidemiology. In: Basit A, Ahmedani MY, editors. *BIDE's Diabetes Desk Book: For Healthcare Professionals*. Cambridge, England: Elsevier; 2024. p. 19-42. <https://doi.org/10.1016/b978-0-443-22106-4.00022-x>.
6. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. *Health Sci Rep*. 2024;7(3): e2004. [PubMed ID: 38524769]. [PubMed Central ID: PMC10958528]. <https://doi.org/10.1002/hsr2.2004>.
7. Sharif KM, Rahman MM, Zaidul ISM, Jannatul A, Akanda MJH, Mohamed A, et al. Pharmacological relevance of primitive leafy cactuses *Pereskia*. *Res J Biotechnol*. 2013;8(12):134-42.
8. Agostini-Costa TDS. Genetic and environment effects on bioactive compounds of *Opuntia* cacti – A review. *J Food Compos Anal*. 2022;109. <https://doi.org/10.1016/j.jfca.2022.104514>.
9. Zareisehdezadeh S, Tan CH, Koh HL. A Review of Botanical Characteristics, Traditional Usage, Chemical Components, Pharmacological Activities, and Safety of *Pereskia bleo* (Kunth) DC. *Evid Based Complement Alternat Med*. 2014;2014:326107. [PubMed ID: 25083311].

24987426]. [PubMed Central ID: PMC4060302]. <https://doi.org/10.1155/2014/326107>.

10. Butterworth CA, Wallace RS. Molecular Phylogenetics of the Leafy Cactus Genus *Pereskia* (Cactaceae). *Syst Bot.* 2005;30(4):800-8. <https://doi.org/10.1600/036364405775097806>.
11. Nyffeler R, Eggli U. A farewell to dated ideas and concepts: molecular phylogenetics and a revised suprageneric classification of the family Cactaceae. *Schumannia*. 2010;6:109-49.
12. Lode J. Leuenbergeria, a new genus in Cactaceae. *Cact Advent Int.* 2013;90:4-8.
13. Royal Botanic Gardens. *Leuenbergeria bleo (Kunth) Lodé*. Plants of the World Online; 2024. Available from: <https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:6046184-4-2>.
14. World Flora Online. *Leuenbergeria bleo (Kunth) Lodé*. 2025. Available from: <http://www.worldfloraonline.org/taxon/wfo-0001431294>.
15. Zareisehdehizadeh S, Siew Y, Wee H, Tan C, Koh H. Medicinal uses of a leafy cactus, *Pereskia bleo*, in Singapore: A survey on the users' knowledge and their perceptions. *Int J Herb Med.* 2022;10(1):1-7. <https://doi.org/10.22271/flora.2022.v10.i1a.788>.
16. Mohd-Salleh SF, Wan-Ibrahim WS, Ismail N. *Pereskia bleo* Leaves Extract Induces Cell Death via Cell Cycle Arrest and Apoptosis in Cervical Cancer Cells HeLa. *Nutr Cancer.* 2020;72(5):826-34. [PubMed ID: 31433251]. <https://doi.org/10.1080/01635581.2019.1654530>.
17. Siska S, Hanani E, Bariroh T, Febrianto B, Pratiwi ADAP, Yaner NN, et al. Effect of the ethanol extract of *Pereskia bleo* (Kunth) DC. on the blood pressure and electrolyte levels of hypertensive rats. *J Herbmed Pharmacol.* 2023;12(3):448-52. <https://doi.org/10.34172/jhp.2023.50>.
18. Johari MA, Khong HY. Total Phenolic Content and Antioxidant and Antibacterial Activities of *Pereskia bleo*. *Adv Pharmacol Sci.* 2019;2019:7428593. [PubMed ID: 30719037]. [PubMed Central ID: PMC6334350]. <https://doi.org/10.1155/2019/7428593>.
19. Mat Darus NA, Mohamad J. Antidiabetic Activity of *Pereskia bleo* Aqueous Extracts in Alloxan Induced Diabetic Rats. *J Pharm Res.* 2017;1(7).
20. Guilhon CC, Abdul Wahab IR, Boylan F, Fernandes PD. Central Antinociceptive and Mechanism of Action of *Pereskia bleo* Kunth Leaves Crude Extract, Fractions, and Isolated Compounds. *Evid Based Complement Alternat Med.* 2015;2015:915927. [PubMed ID: 26273315]. [PubMed Central ID: PMC4530238]. <https://doi.org/10.1155/2015/915927>.
21. Liu ZJ, Zhu CF. Causal relationship between insulin resistance and sarcopenia. *Diabetol Metab Syndr.* 2023;15(1):46. [PubMed ID: 36918975]. [PubMed Central ID: PMC10015682]. <https://doi.org/10.1186/s13098-023-01022-z>.
22. Espino-Gonzalez E, Dalbram E, Mounier R, Gondin J, Farup J, Jessen N, et al. Impaired skeletal muscle regeneration in diabetes: From cellular and molecular mechanisms to novel treatments. *Cell Metab.* 2024;36(6):1204-36. [PubMed ID: 38490209]. <https://doi.org/10.1016/j.cmet.2024.02.014>.
23. Lanza U, Alongi M, Frossi B, Pucillo C, Anese M, Nicoli MC. Investigating the hypoglycaemic potential of processed apple and acarbose combination in vitro, ex vivo, and in vivo: the role of quercetin-3-glucoside in steering alpha-glucosidase inhibition. *Food Funct.* 2025;16(5):1772-80. [PubMed ID: 39927822]. <https://doi.org/10.1039/d4fo06307d>.
24. Rao Y, Yu H, Gao L, Lu YT, Xu Z, Liu H, et al. Natural alkaloid bouchardatine ameliorates metabolic disorders in high-fat diet-fed mice by stimulating the sirtuin 1/liver kinase B-1/AMPK axis. *Br J Pharmacol.* 2017;174(15):2457-70. [PubMed ID: 28493443]. [PubMed Central ID: PMC5513868]. <https://doi.org/10.1111/bph.13855>.
25. Shahidi F, Danielski R. Review on the Role of Polyphenols in Preventing and Treating Type 2 Diabetes: Evidence from In Vitro and In Vivo Studies. *Nutrients.* 2024;16(18). [PubMed ID: 39339759]. [PubMed Central ID: PMC11435057]. <https://doi.org/10.3390/nut16183159>.
26. Sim KS, Sri Nurestri AM, Sinniah SK, Kim KH, Norhanom AW. Acute oral toxicity of *Pereskia bleo* and *Pereskia grandifolia* in mice. *Pharmacogn Mag.* 2010;6(21):67-70. [PubMed ID: 20548939]. [PubMed Central ID: PMC2881650]. <https://doi.org/10.4103/0973-1296.59969>.
27. Nkono BLNY, Hamadjida A, Gounkagou D, Ntchapda F, Dongmo SS, Kamtchouing P. Hypoglycemic and antihyperglycemic effects of *Abelmoschus esculentus* and *Alchornea cordifolia* in normal and alloxan-induced diabetic rats. *Pharmacol Res Mod Chin Med.* 2024;13. <https://doi.org/10.1016/j.prmcm.2024.100531>.
28. Omabe M, Nwudele C, Omabe KN, Okorocha AE. Anion Gap Toxicity in Alloxan Induced Type 2 Diabetic Rats Treated with Antidiabetic Noncytotoxic Bioactive Compounds of Ethanolic Extract of *Moringa oleifera*. *J Toxicol.* 2014;2014:406242. [PubMed ID: 25548560]. [PubMed Central ID: PMC4274870]. <https://doi.org/10.1155/2014/406242>.